Flipside Finance
AZ

AstraZeneca PLC

AZNEquity
$169.64-0.99%
24h Volume: $0.00B

AI Summary

Updated 8h ago

AstraZeneca PLC (AZN) is in a mixed position

AstraZeneca PLC (AZN) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme that demands attention. For reference: Flow Score 31/100, Trend & Momentum Score 19/100.

27Below average
Market position

Market Positioning

18Compressed
Extension
33Below avg
Momentum
29Below avg
Flow
66Above avg
Volatility

What's Happening

Updated 48d ago

AZN beat Q1 earnings expectations on April 29

AstraZeneca reported first-quarter 2026 EPS of $2.58 on April 29, topping the $1.53 consensus estimate cited by Public.com by 68.63%. The surprise matters because it signals the underlying earnings base is still running ahead of sell-side expectations, which can support valuation confidence even without a major rerating immediately following the print.

The Bigger Picture

Updated 6d ago
Macro context will be updated shortly
Flow Score: 33/100Trend Score: 19/1003-Month Return: -12.0%

Upcoming Catalysts

Updated 48d ago
Jul 28Q2 2026 earnings releasePassed

AstraZeneca’s next earnings print is the main near-term catalyst. Investors will focus on whether the company can extend the April earnings beat and confirm that 2026 EPS expectations still have room to rise.

Jul 28Earnings call and guidance updatePassed

Management commentary on product momentum, margin discipline, and capital allocation will matter as much as the reported numbers. Any shift in full-year guidance or tone on pipeline conversion could move expectations for the second half of 2026.

Aug 14Likely ex-dividend timing window

AstraZeneca’s prior ex-dividend date listed by HL.co.uk was 19 February 2026, so investors will be watching for the next dividend-related schedule update around the usual late-summer timing window. For income-oriented holders, the exact declaration and ex-date can help frame short-term demand for the shares.

Positive Catalyst
Earnings

Technical Analysis

Market Positioning

Where does this asset sit across four dimensions? Extension (how stretched price is vs its own history), Momentum (RSI, MACD, rate of change), Flow (volume and money flow), and Volatility (how quiet or active). Each bar shows a 0–100 percentile compared to the last year of data. Key levels show the nearest demand and supply zones from our confluence analysis.

Extension
[avg: 18th]
18thpercentile
Low
Normal
High
18th percentile
Momentum
[avg: 33rd]
33rdpercentile
Low
Normal
High
33rd percentile
Flow
[avg: 29th]
29thpercentile
Low
Normal
High
29th percentile
Volatility
[avg: 66th]
66thpercentile
Low
Normal
High
66th percentile

Key Levels

Demand: $163–$165 (3.3% below)
score: 1.20
Supply: $169–$175 (1.3% above)
score: 1.80
View full Key Levels section →

Looking at the full picture for AstraZeneca PLC (AZN): extension is below average (18th percentile), momentum is slightly below average (33rd percentile), flow is below average (29th percentile), volatility is slightly above average (66th percentile).

Conclusion

AstraZeneca PLC (AZN) is in a mixed position. Some indicators are above average, others below, but nothing is at an extreme level that defines the current setup strongly in either direction. There is not a strong signal here in either direction. This is an asset to watch rather than act on right now. These readings update daily. Flipside shows what is happening now, grounded in the data — not what will happen next.

Your portfolio. Your context. Smarter decisions.

Connect your holdings and let the Flipside Agent analyze market changes through the lens of your portfolio.

AI + Portfolio

Personalized insights based on your actual holdings

Daily Briefing

Major market movements delivered to your inbox

Watchlists

Track the assets that matter most to you

Create your free account

No credit card required